Comparison of three tracking methods to assess usage of two pediatric powered mobility devices for young children with cerebral palsy.

Assist TechnolNov 4, 2025 (epub)
Clinical ResearchPediatrics

Bethany M Sloane, Mia Hoffman, Samuel W Logan et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized-order comparative study assessed three methods for tracking use of two powered mobility devices in 12 children with cerebral palsy. Each child used a Modified Ride-on Car (MROC) and a Permobil Explorer Mini (EM) for eight consecutive weeks per device in home and community settings. Tracking methods showed no significant differences for the MROC; for the EM, session duration differed only between GPS trackers and caregiver-reported activity logs. Caregiver logs indicated greater total usage minutes and session duration for the EM than the MROC, whereas GPS data did not show this difference.

Key findings

  • For the MROC, integrated loggers, GPS trackers, and caregiver activity logs showed no significant differences in usage metrics.
  • For the EM, session duration differed only between GPS trackers and caregiver-reported activity logs.
  • Caregiver logs showed significantly greater total usage minutes and session duration for the EM than the MROC; GPS tracking did not.
  • Correlations among tracking methods varied for both devices.

Why it matters

Device-use estimates can depend on the tracking method and the powered mobility device being assessed. This matters when evaluating whether children are using mobility interventions and interpreting usage as part of outcome assessment. The variable agreement reported here underscores that usage measures from different sources may not be interchangeable.

What to keep in mind

The study included 12 children, and tracking-method comparisons were conducted across only two devices and an eight-week use period per device.

Source

Published in Assist Technol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.